{"id":24057,"date":"2024-04-29T11:17:56","date_gmt":"2024-04-29T09:17:56","guid":{"rendered":"https:\/\/ggba.swiss\/?p=24057"},"modified":"2024-04-29T11:17:57","modified_gmt":"2024-04-29T09:17:57","slug":"azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/","title":{"rendered":"Azure Cell Therapies, FireFly Fusion and Antion Biosciences receive FIF support"},"content":{"rendered":"\n<p>Azure Cell Therapies, emerging from the University of Geneva and led by <a href=\"https:\/\/www.linkedin.com\/in\/m-bilal-fares\">Dr. Bilal Fares<\/a>, received a CHF 50,000 grant to enhance their development of cell therapies for Parkinson&#8217;s disease. This initiative represents a major step forward in personalized medicine and demonstrates the potential of advanced biotechnology to address complex health challenges.<\/p>\n\n\n\n<p><a href=\"https:\/\/fireflyfusion.energy\/\">FireFly Fusion<\/a>, co-founded by long-time CERN physicist Rustem Ospanov and EPFL fusion scientist Justin Ball, was also granted CHF 50,000. This funding will boost their efforts in developing nuclear fusion technology, aiming to create sustainable and clean energy solutions. Their work on standard tokamaks could eventually pave the way to commercially viable fusion energy, which would be a major step forward in terms of environmental sustainability.<\/p>\n\n\n\n<p>Meanwhile, <a href=\"https:\/\/antionbio.com\/\">Antion Biosciences<\/a> has received a seed loan of CHF 100,000 to advance its innovative gene-editing technologies. Under the leadership of Marco Alessandrini and CFO G\u00e9rald Thom\u00e9, Antion is focused on improving the safety and accessibility of cell and gene therapies for complex diseases, promising significant impact on medical treatments.<\/p>\n\n\n\n<p>The <a href=\"https:\/\/www.fongit.ch\/financing\">FIF<\/a>, supported by the State of Geneva, FONGIT, the Geneva Chamber of Commerce, the United Nations International Trade Center, and the United Nations Environment Agency, continues to support innovative projects that align with the United Nations Sustainable Development Goals.<\/p>\n\n\n\n<p>This funding initiative not only strengthens Geneva&#8217;s position as a hub for technological innovation, but also underscores the importance of collaborative efforts to achieve significant advances in the global health and energy sectors.<\/p>\n\n\n\n<figure class=\"wp-block-embed aligncenter is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" title=\"The Fongit Innovation Fund explained (Q&amp;A with Emmanuel de Watteville)\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/aI7yukxRRXI?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Azure Cell Therapies, FireFly Fusion, and Antion Biosciences are the latest beneficiaries of the FONGIT Innovation Fund (FIF), receiving funds to advance their pioneering work in health and energy solutions.<\/p>\n","protected":false},"author":6,"featured_media":24058,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[838],"tags":[912,936,894,954,902,899],"class_list":["post-24057","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-environment","tag-biotech","tag-energy","tag-financing","tag-gene-therapy","tag-personalized-medicine","tag-sustainability"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Azure Cell, FireFly Fusion and Antion receive FIF support | GGBa<\/title>\n<meta name=\"description\" content=\"Azure Cell Therapies, FireFly Fusion, and Antion Biosciences are the latest beneficiaries of the FONGIT Innovation Fund (FIF).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Azure Cell, FireFly Fusion and Antion receive FIF support | GGBa\" \/>\n<meta property=\"og:description\" content=\"Azure Cell Therapies, FireFly Fusion, and Antion Biosciences are the latest beneficiaries of the FONGIT Innovation Fund (FIF).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-29T09:17:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-29T09:17:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/FIF-Geneva-2360x1622-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2360\" \/>\n\t<meta property=\"og:image:height\" content=\"1622\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Azure Cell Therapies, FireFly Fusion and Antion Biosciences receive FIF support\",\"datePublished\":\"2024-04-29T09:17:56+00:00\",\"dateModified\":\"2024-04-29T09:17:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/\"},\"wordCount\":260,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/FIF-Geneva-2360x1622-1.jpg\",\"keywords\":[\"Biotech\",\"Energy\",\"Financing\",\"Gene Therapy\",\"Personalized Medicine\",\"Sustainability\"],\"articleSection\":[\"Business environment\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/\",\"url\":\"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/\",\"name\":\"Azure Cell, FireFly Fusion and Antion receive FIF support | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/FIF-Geneva-2360x1622-1.jpg\",\"datePublished\":\"2024-04-29T09:17:56+00:00\",\"dateModified\":\"2024-04-29T09:17:57+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Azure Cell Therapies, FireFly Fusion, and Antion Biosciences are the latest beneficiaries of the FONGIT Innovation Fund (FIF).\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/FIF-Geneva-2360x1622-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/FIF-Geneva-2360x1622-1.jpg\",\"width\":2360,\"height\":1622,\"caption\":\"The FIF has once again highlighted its commitment to propelling tech innovation in Geneva by awarding significant financial support to three promising projects.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Azure Cell Therapies, FireFly Fusion and Antion Biosciences receive FIF support\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Azure Cell, FireFly Fusion and Antion receive FIF support | GGBa","description":"Azure Cell Therapies, FireFly Fusion, and Antion Biosciences are the latest beneficiaries of the FONGIT Innovation Fund (FIF).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/","og_locale":"en_US","og_type":"article","og_title":"Azure Cell, FireFly Fusion and Antion receive FIF support | GGBa","og_description":"Azure Cell Therapies, FireFly Fusion, and Antion Biosciences are the latest beneficiaries of the FONGIT Innovation Fund (FIF).","og_url":"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-04-29T09:17:56+00:00","article_modified_time":"2024-04-29T09:17:57+00:00","og_image":[{"width":2360,"height":1622,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/FIF-Geneva-2360x1622-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Azure Cell Therapies, FireFly Fusion and Antion Biosciences receive FIF support","datePublished":"2024-04-29T09:17:56+00:00","dateModified":"2024-04-29T09:17:57+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/"},"wordCount":260,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/FIF-Geneva-2360x1622-1.jpg","keywords":["Biotech","Energy","Financing","Gene Therapy","Personalized Medicine","Sustainability"],"articleSection":["Business environment"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/","url":"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/","name":"Azure Cell, FireFly Fusion and Antion receive FIF support | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/FIF-Geneva-2360x1622-1.jpg","datePublished":"2024-04-29T09:17:56+00:00","dateModified":"2024-04-29T09:17:57+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Azure Cell Therapies, FireFly Fusion, and Antion Biosciences are the latest beneficiaries of the FONGIT Innovation Fund (FIF).","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/FIF-Geneva-2360x1622-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/FIF-Geneva-2360x1622-1.jpg","width":2360,"height":1622,"caption":"The FIF has once again highlighted its commitment to propelling tech innovation in Geneva by awarding significant financial support to three promising projects."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Azure Cell Therapies, FireFly Fusion and Antion Biosciences receive FIF support"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/24057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=24057"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/24057\/revisions"}],"predecessor-version":[{"id":24061,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/24057\/revisions\/24061"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/24058"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=24057"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=24057"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=24057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}